Maximum quantity allowed is 999
	  Please select the quantity
	
CAS RN: 23672-07-3 | Product Number: I0821
(S)-(-)-Sulpiride
 
									 
							Purity: >98.0%(T)(HPLC)
Synonyms:
						
						- (S)-N-[(1-Ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide
- Levosulpiride
Product Documents:
                    
				
						* Please contact our distributors or
						TCI
						to order TCI products.
						* The storage conditions are subject to change without notice.
				
| Product Number | I0821 | 
| Purity / Analysis Method   | >98.0%(T)(HPLC) | 
| Molecular Formula / Molecular Weight | C__1__5H__2__3N__3O__4S = 341.43 | 
| Physical State (20 deg.C) | Solid | 
| Storage Temperature   | Refrigerated (0-10°C) | 
| Condition to Avoid | Heat Sensitive | 
| CAS RN | 23672-07-3 | 
| Reaxys Registry Number | 3563418 | 
| PubChem Substance ID | 135726922 | 
| Merck Index (14) | 8989 | 
| MDL Number | MFCD00055220 | 
Specifications
		  | Appearance | White to Light yellow powder to crystal | 
| Purity(HPLC) | min. 98.0 area% | 
| Purity(Nonaqueous Titration) | min. 98.0 % | 
| Melting point | 185.0 to 189.0 °C | 
| Specific rotation [a]20/D | -67.0 to -71.0 deg(C=3, DMF) | 
		Properties (reference)
	| Melting Point | 187 °C | 
| Specific Rotation | -69° (C=3,DMF) | 
| Solubility (soluble in) | Dimethylformamide | 
 
						 GHS
						  
								 Related Laws: 
							   | RTECS# | BZ3400100 | 
 
						Transport Information:
							| H.S.code* | 2935.90-000 | 
			Application
		
			(S)-(-)-Sulpiride: A Dopamine D2 Receptor Antagonist
		
		(S)-(-)-Sulpiride (or levosulpiride) is the active enantiomer of (±)-sulpiride [S0501], and a substituted benzamide-type atypical antipsychotic having the properties of dopamine D2 receptor antagonist. (The product is for research purpose only.)
References
- The effects of S(-) and R(+) sulpiride, metoclopramide, cisapride and domperidone on the small intestine suggest DA2-receptors are involved in the control of small intestinal transit time in rats
- Disposition of enantiomers of sulpiride in humans and rats
- Pharmacotoxicological aspects of levosulpiride (a review)
- Levosulpiride: A review of its clinical use in psychiatry (a review)
- Hydrophilic interaction liquid chromatography-tandem mass spectrometry for the determination of levosulpiride in human plasma
- Spectrophotometric estimation of levosulpiride in bulk drug and formulations
			PubMed Literature
		Product Articles
  		        Product Documents (Note: Some products will not have analytical charts available.)
 		Safety Data Sheet (SDS)
                	  
                      
						Please select Language.
		         
                 
        			
					The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
				     
						
						
						
							Please enter Lot Number
						
							Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
                        
				
                
	         	
                
                
    		Sample C of A
                    This is a sample C of A and may not represent a recently manufactured lot of the product.
	         	
                A sample C of A for this product is not available at this time.
Analytical Charts
					 
			  
		  
                                			
                                				        
                                						
                                						
                                						
                                							Please enter Lot Number
                                						
                                							Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
                                						
                                				
                                				
                                	         	
                                                
                                                    The requested analytical chart is not available. Sorry for the inconvenience.

 
       
                                 
	